The first GLP-1 receptor agonist, exenatide (Byetta), was FDA-approved on April 28, 2005 built from a peptide isolated in the venom of a Gila monster
Your provider will customize your dosing schedule based on your response and tolerance
Besides tasting like a creamy treat in my coffee, its an easy 20 grams of protein, which makes it easier to hit my macro goals, she says
What's New: July 2026 Update TRIUMPH-4 confirmed: Retatrutide 28.7% weight loss in Phase 3 (December 2025) final data, not preliminary TRIUMPH-1 CONFIRMED (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients without diabetes pivotal trial met all primary endpoints Availability unchanged: Retatrutide still investigational, no FDA approval until late 2027 at earliest Tirzepatide still the best available option: 22.5% weight loss, FDA-approved, available today TRANSCEND-T2D-1 confirmed (June 2026): -2.0% HbA1c and 16.8% weight loss in type 2 diabetes patients a separate diabetes-specific Phase 3 program NDA timeline on track: industry estimates continue to expect Q4 2026 filing, following TRIUMPH-1's positive readout Introduction The evolution of weight loss medications has progressed rapidly from single-agonist drugs to multi-agonist approaches
Dogs with DCM usually show an enlarged heart chamber on one or both sides, and dense fluid-filled lungs
In the STEP UP T2D study, dysesthesia, which includes unusual skin sensations like tingling or burning, was more frequently observed at a dose of 7.2 mg
